Medici Brands Closes $250 Million Round at $2.25 Billion Valuation

Medici Brands, the multi-brand CPG platform founded by Peter Rahal, has closed a $250 million funding round at a $2.25 billion valuation, a raise that lifts Rahal's estimated net worth to $1.9 billion and marks one of the more consequential financing events in the consumer goods sector this year.

The company's portfolio spans three brands: David, HallPass, and Epogee. Medici says it is on track to exceed $300 million in revenue for 2026, per the company, a figure that would place the business among the larger independent CPG platforms at its stage of development.

Rahal's trajectory has become a reference point in the industry. He co-founded RXBAR with an initial outlay of $10,000 and ultimately sold the brand for $600 million. Medici represents his second major vehicle in the category, this time built around a portfolio approach rather than a single brand scaled to exit.

Why it matters

A $2.25 billion valuation set against a reported $300 million revenue target implies a multiple that reflects investor conviction in the platform model itself, not merely in any individual product line. Roll-up strategies in CPG have produced uneven results historically: several well-capitalised holding companies found that managing multiple brands under one roof created operational friction rather than leverage. The Medici raise suggests investors believe a tightly curated, founder-led portfolio can navigate those pressures, particularly when anchored by an operator with a large prior exit. The round also reinforces a concentration trend in consumer-sector capital, where larger checks are flowing toward founders with demonstrated track records rather than spreading broadly across early-stage single-brand bets. For the broader market, Rahal's journey from a $10,000 founding investment to a $1.9 billion personal valuation in two distinct CPG cycles is a data point that will shape how founders and investors frame the next generation of brand-building strategies.

What to watch

The most immediate open question is whether Medici's $300 million revenue target for 2026 holds through year-end. Beyond that, the deployment of $250 million will signal whether the company intends to expand the portfolio through acquisition or invest in scaling its existing three brands. A fourth or fifth addition would provide the clearest test yet of whether the Medici model is a repeatable system or a function of the specific brands it currently holds.

Featured on @cpglatest: see the post